Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis. Issue 3 (25th December 2020)
- Record Type:
- Journal Article
- Title:
- Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis. Issue 3 (25th December 2020)
- Main Title:
- Galectins‐1, ‐3, ‐7, ‐8 and ‐9 as prognostic markers for survival in epithelial ovarian cancer: A systematic review and meta‐analysis
- Authors:
- Pergialiotis, Vasilios
Papoutsi, Eleni
Androutsou, Anastasia
Tzortzis, Andrianos‐Serafeim
Frountzas, Maximos
Papapanagiotou, Angeliki
Kontzoglou, Konstantinos - Abstract:
- Abstract: Background: Galectins are a family of proteins that have recently emerged as regulators of cancer biology. Objectives: To investigate the impact of peritumoral and tumoral galectin expression on ovarian cancer prognosis. Search strategy: We searched Medline, Cochrane, and EMBASE databases from inception until March 22, 2020. Selection criteria: All studies correlating galectins and ovarian cancer prognosis were selected. Data collection and analysis: The literature search presented 11 studies, which contained 1034 patients. Meta‐analysis was performed with RevMan 5.3 software. Main results: Studies were stratified into two groups depending on the location of galectin expression (peritumoral stroma or nucleus/cytoplasm of tumor cells). Tumoral galectin‐7 and galectin‐9 expression was significantly associated with poor overall survival (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.32–3.21, P = 0.001; OR 1.71, 95% CI 1.27–2.30, P < 0.001, respectively). The total effect of high tumoral expression of galectins in overall survival and progression‐free survival was significant (OR 1.51, 95% CI 1.02–2.23, P = 0.04; OR 2.76, 95% CI 1.73–4.40, P < 0.001, respectively). Conclusions: Our results suggest that galectins are implicated in ovarian cancer prognosis; however, further research is needed to ascertain their actual importance as well as their diagnostic accuracy. Synopsis: Overall, our study highlights that tumoral (cytoplasmic or nuclear) galectin‐7, ‐9Abstract: Background: Galectins are a family of proteins that have recently emerged as regulators of cancer biology. Objectives: To investigate the impact of peritumoral and tumoral galectin expression on ovarian cancer prognosis. Search strategy: We searched Medline, Cochrane, and EMBASE databases from inception until March 22, 2020. Selection criteria: All studies correlating galectins and ovarian cancer prognosis were selected. Data collection and analysis: The literature search presented 11 studies, which contained 1034 patients. Meta‐analysis was performed with RevMan 5.3 software. Main results: Studies were stratified into two groups depending on the location of galectin expression (peritumoral stroma or nucleus/cytoplasm of tumor cells). Tumoral galectin‐7 and galectin‐9 expression was significantly associated with poor overall survival (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.32–3.21, P = 0.001; OR 1.71, 95% CI 1.27–2.30, P < 0.001, respectively). The total effect of high tumoral expression of galectins in overall survival and progression‐free survival was significant (OR 1.51, 95% CI 1.02–2.23, P = 0.04; OR 2.76, 95% CI 1.73–4.40, P < 0.001, respectively). Conclusions: Our results suggest that galectins are implicated in ovarian cancer prognosis; however, further research is needed to ascertain their actual importance as well as their diagnostic accuracy. Synopsis: Overall, our study highlights that tumoral (cytoplasmic or nuclear) galectin‐7, ‐9 expression negatively affects overall survival among patients with ovarian cancer. … (more)
- Is Part Of:
- International journal of gynaecology and obstetrics. Volume 152:Issue 3(2021)
- Journal:
- International journal of gynaecology and obstetrics
- Issue:
- Volume 152:Issue 3(2021)
- Issue Display:
- Volume 152, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 152
- Issue:
- 3
- Issue Sort Value:
- 2021-0152-0003-0000
- Page Start:
- 299
- Page End:
- 307
- Publication Date:
- 2020-12-25
- Subjects:
- Epithelial ovarian cancer -- Galectins -- Meta‐analysis -- Prognosis
Gynecology -- Periodicals
Obstetrics -- Periodicals
Electronic journals
618 - Journal URLs:
- http://www.clinicalkey.com/dura/browse/journalIssue/00207292 ↗
http://www.sciencedirect.com/science/journal/00207292 ↗
https://obgyn.onlinelibrary.wiley.com/journal/18793479 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1002/ijgo.13471 ↗
- Languages:
- English
- ISSNs:
- 0020-7292
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15774.xml